Warfarin pharmacogenetics: economic considerations

Pharmacoeconomics. 2007;25(11):899-902. doi: 10.2165/00019053-200725110-00001.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / economics*
  • Anticoagulants / therapeutic use*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Costs and Cost Analysis
  • Cytochrome P-450 CYP2C9
  • Humans
  • Pharmacogenetics*
  • Warfarin / economics*
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Warfarin
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases